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Abstract 
BACKGROUND: Epilepsy is the most frequent chronic neurologic condition in childhood. Its clinical diagnosis is 
based on electroencephalograms (EEG) and neuroimaging techniques. MicroRNAs (miRNAs) modulate gene 
expression of several genes and are aberrantly expressed in several diseases. 
AIM: Evaluation of using circulating miR-106b and miR-146a as diagnostic and prognostic biomarkers in children 
patients with epilepsy. 
METHODS: Thirty epileptic children and twenty controls were enrolled in our study. They were assessed for the 
expression pattern of miR-106b and miR-146a in plasma using quantitative real-time PCR and determination of 
plasma Immunoglobulin levels. 
RESULTS: MiR-146a and miR-106b expression patterns were significantly up-regulated in children patients than 
that in normal controls. Plasma Immunoglobulins were differentially expressed in epileptic patients in comparison 
with healthy controls. No correlations were found between expression levels of miRNAs (miR-146a and miR-
106b) and clinical data or immunoglobulin levels in children patients with epilepsy. 
CONCLUSION: Our findings suggest that up-regulated plasma miR-106b and miR-146a could be used as 
biomarkers for epilepsy evaluation. 
 
 
Introduction 
 
Epilepsy is a common childhood neurological 
condition and a worldwide major public health concern 
[1]. It’s estimated that about 4-10% of the world 
population is affected by it [2]. At the pediatric side, 
0.5% to 1% of children are suffered from epilepsy. 
Nowadays, its occurrence is decreased in high-
income countries. In Arab countries, the estimated 
prevalence of epilepsy in children ranges from 3.6 to 
10.5/1000 [3]. It is characterised by recurrent 
seizures, which are either brief generalised or partial 
involuntary movements that may be accompanied by 
loss of consciousness [4]. Those seizures are due to 
excessive electrical discharges in a group of brain 
cells. They may be a very brief lapse of attention to 
severe long convulsions [5]. 
Diagnosis of epilepsy is challenging; the 
principles of the neurological diagnosis should be 
followed, including what? (clinical diagnosis), where? 
(topographical diagnosis), and why? (etiological 
diagnosis) with detailed history, general and 
neurologic examination accompanied with the right 
choice of complementary evaluations as EEG which 
despite that normal EEG does not exclude epilepsy 
diagnosis and even 5-8% of normal children may have 
epileptiform discharges on the EEG, Cerebral imaging 
(MRI) may also be used [6],
 
and hence biomarkers 
may be considered novel tools for diagnosis which 
could facilitate the treatment afterwards [7]. MiRNAs 
are a class of short non-coding RNAs which regulate 
the expression of a variety of genes and enter in 
various biological functions as cell differentiation, 
development, metabolism, immune responses, and 
carcinogenesis [8]. More than 50% of the identified 
miRNAs are expressed in the brain. They are 
incorporated in many brain functions which are of 
importance to epileptogenesis, including cell death, 
neurogenesis, and synaptic plasticity [9]. 
The changing miRNA profiles in biofluids may 
be considered as useful biomarkers of 
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epileptogenesis. Targeting Key miRNAs has been 
shown to suppress or exacerbate seizures and alter 
brain excitability, indicating a potential for miRNA-
based therapeutics in epilepsy [10]. 
Recent reports have shown that certain 
miRNAs (e.g., miR-132) control several 
epileptogenesis-related processes, such as cell death 
and neuroinflammation [11], [12]. Mir-21 has also 
been reported to be increased in models of prolonged 
seizures in immature rats [13]. MiR-34a expression is 
controlled by p53, which is upregulated and 
contributes to neuronal death provoked by seizures 
[14], [15]. MiR-184 was known as the most 
upregulated miRNA in the hippocampus after an 
episode of brief, non-harmful seizures, a model of 
epileptic preconditioning and a rich source of 
neuroprotective pathways [16]. Silencing miR-184 
significantly increased seizure-induced neuronal death 
in two animal models of status epilepticus (SE) [16]. 
Mice with a conditional deletion of miR-128 were 
found to develop fatal epilepsy [17]. MiR-134 is a 
brain-enriched miRNA overexpressed after SE and in 
experimental and human epilepsy [18], [19].  
People with epilepsy may show various types 
of immunological abnormalities, such as low serum 
IgA levels, lack of IgG subclass and presence of 
certain types of antibodies [20]. 
In this study, we aim to evaluate using of 
circulating miRNAs (miR-106b and miR-146a) as 
diagnostic and prognostic biomarkers in epilepsy 
through investigating their expression patterns in 
epileptic patients compared to healthy controls, 
examining their correlations with the clinical 
characteristics and clinical data of patients, and 
comparing their expression levels with 
Immunoglobulin levels in epileptic patients. 
 
 
Patients and Methods 
 
This study was approved by the Research 
Ethics Committee, Faculty of Medicine for Girls, Al-
Azhar University (Cairo, Egypt). Written informed 
consent from both parents/guardians and oral 
informed consent from children were taken after full 
explanation of the study according to ICMJE 
Recommendations for the Protection of Research 
Participants. 
This study was a case-control study. Thirty 
patients with epilepsy and 20 healthy controls with 
matched age and sex and having age ranging from 5 
to 15 years were involved in the study. Patients were 
recruited from Pediatrics Neurology clinic, Al-Zahraa 
University Hospital, Cairo, Egypt, from January 2019 
to June 2019. Inclusion criteria: Idiopathic epilepsy by 
clinical examination and EEG. Exclusion criteria: 
Patients with other chronic diseases or psychiatric 
disorders, history of autoimmune diseases, history of 
infection 2 weeks before sample collection. Patients in 
this study were subjected to full medical history with 
special emphasis on the character of seizures (type, 
age of onset and duration of the seizures) and full 
neurological examination. 
 
RNA extraction and quantitative real‑time 
 PCR 
MicroRNA was extracted and isolated from 
plasma of all subjects of the study populations using 
miRNeasy Mini kit of Qiagen (Germany) according to 
the manufacturer’s instructions. For miRNA-specific 
reverse transcription, microRNA was reverse-
transcribed to cDNA using TaqMan
®
 MicroRNA 
Reverse Transcription Kit (Applied Biosystems) and 
using specific primers according to the manufacturer’s 
instructions. Reverse transcription was performed 
under the following conditions: 30 min at 16°C, 30 min 
at 42°C and followed by 5 min at 85°C and the 
resulting cDNA was kept at -80°C until use. 
A real-time quantitative PCR (qRT-PCR) was 
carried out to quantify the expression levels in 
triplicate of mature miR-146a and miR-106b using 
TaqMan® MicroRNA Assay kit and TaqMan
®
 
Universal Master Mix (Applied Biosystems) using 
7500 fast real-time PCR system according to the 
manufacturer’s instructions. RNU6B was used as an 
endogenous control to normalise the expression 
levels of target miRs. Relative quantification (Rq) of 
miRNA expression was calculated using the 2
−ΔΔCT
 
threshold cycle method. ΔCt was determined by 
subtracting the Ct values for RUN6B from the Ct 
values for the gene of interest. Q RT-PCR was 
performed under the following conditions: 2 min at 
50°C, 10 min at 95°C, followed by 50 cycles at 95°C 
for 15 s and 60°C for 1 min [21]. 
 
Determination of plasma Immunoglobulin 
 levels (IgA, IgG and IgM) 
Measurement of human Immunoglobulin in 
plasma was performed using the method of 
immunonephlometry [22] (Minineph
TM
, the Binding 
Site Ltd, PO Box 11712, Birmingham, B14 4ZB, U.K). 
 
Statistical analysis 
Data were statistically analyzed using SPSS 
version 16.0 software (SPSS Inc., Chicago, Illinois, 
USA). Independent samples T-Test was used to 
compare gene expression levels of microRNA 
between patients with epilepsy and normal controls. 
Nonparametric Mann-Whitney U test was used for 
comparing Immunoglobulin levels between groups. 
Correlations between microRNA expressions, 
immunoglobulin levels and clinical parameters of 
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patients with epilepsy were analyzed using 
Spearman’s rank correlation. Data were presented as 
mean ± SEM. A P value of less than 0.05 was 
considered statistically significant. Receiver operating 
characteristic (ROC) curve was constructed for miR-
146a and miR-106b to evaluate the efficiency of these 
miRNAs as biomarkers for epileptic patients against 
controls. Area under curve (AUC) values, specificity, 
sensitivity and 95 % confidence intervals for each 
miRNA were calculated. 
 
 
Results 
 
The total number of epileptic patients was 30, 
with 22 males and 8 females. Table 1 shows the 
clinical characteristics of patients. Most of our patients 
(45%) were diagnosed as generalised epilepsy, and 
the lowest percentage (10%) was diagnosed as focal 
epilepsy.  
Table 1: Clinical Characteristics of patients 
Characteristic Epileptic patients Normal healthy controls 
No. of cases 30 20 
Gender, no. male/female 22/8 10/10 
Age, (range) 5-15 5-15 
Disease duration (yrs) mean ± S.E. 6.25 ± 0.59 - 
Types (% of 
Epilepsy) 
Idiopathic 25% 
- 
Focal 10% 
Generalised 45% 
Focal then 
Generalized 
20% 
Medications (Tegretol, Depakine, 
Tiratam) 
25/30 0/20 
 
 
Expression pattern of microRNAs 
Our results indicated that miR-146a 
expression pattern was significantly higher in children 
patients with epilepsy than that in normal controls. 
14.65-fold up-regulation in expression levels of miR-
146a was found in epileptic patients compared to 
healthy controls. Moreover, the expression level of 
miR-106b was significantly up-regulated in patients 
with epilepsy in comparison with healthy controls. The 
level of miR-106b expression was 11.6 fold higher in 
epileptic patients compared to normal controls (Table 
2). 
Table 2: Relative Quantification of miR-146a and miR-106b in 
plasma of epileptic patients in comparison with healthy 
controls  
 N Rq S.E. Sig. 
Mir-146a 30 14.65 4.92 0.004* 
Mir-106b 30 11.6 3 0.002* 
* P < 0.01 versus controls (by Independent Samples T-Test). 
 
ROC Curve of miR-146a and miR-106b for 
 epileptic patients against normal controls 
ROC curve of miR-146a showed a significant 
AUC value of 0.763, a sensitivity of 73.7% and a 
specificity of 60% (P < 0.05). Moreover, miR-106b 
showed a ROC curve with a good significant AUC 
value of 0.885, a sensitivity of 80% and also a 
specificity of 80% (P < 0.001) as shown in Figure 1).  
 
 
Figure 1: ROC curve of miR-146a (top); ROC curve of miR-106b 
(bottom) 
 
Levels of plasma Immunoglobulins in 
 epileptic patients 
Plasma immunoglobulin IgA levels were 
significantly decreased in children patients with 
epilepsy in comparison with healthy children. Also, 
Immunoglobulin IgG levels were significantly lower in 
plasma of epileptic patients than in normal controls. 
However, levels of IgM in children patients with 
epilepsy were comparable to its levels in normal 
controls (Table 3). 
Table 3: Immunoglobulin levels in the plasma of patients with 
epilepsy versus healthy controls  
 groups Mean S.D. S.E. Sig. 
IgA 
Epileptic patients 0.798 0.478 0.119 
0.038* 
Healthy controls 1.22 0.421 0.149 
IgG 
Epileptic patients 8.79 5.234 1.309 
0.024* 
Healthy controls 12.3 4.55 1.608 
IgM 
Epileptic patients 0.796 0.454 0.11 
0.815 
Healthy controls 0.805 0.286 0.101 
* Statistically significant at P < 0.05 versus controls (with Non-parametric Mann-Whitney U 
Test).  
 
Correlations of miR-146a and miR-106b 
 with Immunoglobulin levels of epileptic 
 patients 
Correlation analysis indicated that there are 
no correlations between miR-146a and 
Immunoglobulin levels in patients with epilepsy. Also, 
no correlations were found between miR-106b and 
Basic Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
3968                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
levels of immunoglobulins in epileptic patients (Table 
4). 
Table 4: Correlations of miR-146a and miR-106b with 
Immunoglobulin levels of epileptic patients 
Parameters 
R (Spearman 
Correlation) 
Sig. 
miR-146a expression ~ IgA  -0.024 0.467 
miR-146a expression ~ IgG -0.204 0.242 
miR-146a expression ~ IgM -0.096 0.362 
Parameters 
R (Spearman 
Correlation) 
Sig. 
miR-106b expression ~ IgA 0.096 0.362 
miR-106b expression ~ IgG -0.089 0.376 
miR-106b expression ~ IgM 0.221 0.197 
*Correlation is significant at the 0.01 level (2-tailed). 
 
Correlations of miR-146a and miR-106b 
 with clinical parameters of epileptic 
 patients 
Our analysis revealed that miR-146a 
expression is significantly correlated with the age of 
epileptic patients in a positive correlation. But there 
are no correlations between miR-146a expression and 
the other clinical parameters of epileptic patients 
(Table 5). Furthermore, the miR-106b expression has 
no correlations with any clinical parameter of patients 
with epilepsy (Table 5). 
Table 5: Correlations of miR-146a and miR-106b with clinical 
parameters of epileptic patients 
Parameters 
R (Spearman 
Correlation) 
Sig. 
miR-146a expression ~ Age  0.554* 0.007 
miR-146a expression ~ Gender -0.330 0.084 
miR-146a expression ~ disease duration 0.378 0.055 
miR-146a expression ~seizure duration 0.208 0.196 
Parameters 
R (Spearman 
Correlation) 
Sig. 
miR-106b expression ~ Age -0.007 0.489 
miR-106b expression ~ Gender -0.190 0.211 
miR-106b expression ~ disease duration -0.046 0.423 
miR-106b expression ~ seizure duration 0.202 0.197 
* Correlation is significant at the 0.01 level (1-tailed). 
 
 
Discussion 
 
Epilepsy is considered a chronic severe 
neurological disorder that leads to recurrent seizures 
[23]. Nowadays, there are many emerging studies 
which undergone on animal models, and human 
patients with epilepsy had concluded that epilepsy 
pathogenesis is accompanied by non-neuronal and 
neuronal components [24]. Because of evidence-
based results in experimental models and the clinical 
studies, there’s a strong theory that inflammatory 
processes in the brain is included in the 
etiopathogenesis of seizures and then the formation of 
a chronic epileptic focus [25]. MiRNAs have an 
effective role in inflammatory pathways that occurs 
with epilepsy. MiR-146a and MiR-106b are key 
regulators of the innate immune response in the 
modulation of astrocyte-mediated inflammation [26]. 
Those miRNAs can be used as new therapeutic target 
in epilepsy treatment. MiRNAs are reported to be 
regulated in blood, suggesting that blood miRNAs 
could be used as biomarkers for brain injury and many 
neuronal diseases [10]. 
In this study, we found that miR-146a and 
miR-106b levels were significantly higher in our 
epileptic patients than that in normal controls with 
14.65-fold and 11.6-fold up-regulation in their 
expression levels respectively. These findings are in 
accordance with Wang et al., [27] study which 
confirmed this result either in their training phase with 
30 epileptic patients and 30 controls or in their 
validation phase with 117 epilepsy patients and 112 
controls. 
We also had found the ROC curve result of 
serum miR-106b with a good significant AUC value of 
0.885 for prediction of epilepsy higher than of miR-
146a which showed a significant AUC value of 0.763. 
Our findings go in the same way of An et al., [28] 
whom had their study with measuring miRNAs using 
quantitative RT-PCR in 90 epileptic patients and 
controls. 
We had found that miR-146a expression is 
significantly positively correlated with age of epileptic 
patients. But there are no correlations between miR-
146a expression and miR-106b expression with the 
other clinical parameters of epileptic patients. Those 
results are the same as Wang et al., [27] except what 
we had reached for positive correlation of miR-146a 
expression with age of patients which may indicate 
that miR-146a is affected by it. 
Our study shows that plasma 
immunoglobulins IgA and IgG levels were significantly 
lower in plasma of epileptic patients than in normal 
controls whereas levels of IgM in children patients 
with epilepsy were comparable to its levels in normal 
controls. In fact, this may be attributed to drugs which 
taken for treatment of epilepsy that lowers levels of 
immunoglobulins despite they were high levels before 
treatment [29], [30]. 
Nowadays, there is an increased evidence 
supports miRNA changes in the pathogenesis of 
epilepsy. There is a subset of epilepsy miRNAs which 
should be studied more not only miRNA-146a and 
miRNA-106b to be able to have a clear image on 
biomarkers as our era now is seeking improvement of 
the ways used for current diagnosis and management 
of epilepsy. In other words, combination of the levels 
of miRNAs with EEG, Neuroimaging and clinical 
history will give a good diagnosis and prognosis which 
will pave the path to novel treatment options. 
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